Search
Corcept Therapeutics Inc
CORTAdd to Watchlist
87.910USD
+0.020+0.02%
Close 06/29, 16:00（ET）Quotes delayed by 15 min
9.44BMarket Cap
191.95P/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+0.02%
5 Days
+10.29%
1 Month
+26.51%
6 Months
+10.14%
Year to Date
+152.61%
1 Year
+20.06%
Key Figures
87.440Open
89.235High
154.00Volume
191.95P/E TTM
19.81P/E Dynamic
--Dividend TTM
0.00%Turnover Ratio
87.890Prev. Close
86.585Low
11.26KTurnover
66.82P/E Static
14.79P/B
0.00%Div Yield TTM
5.70%ROA
91.00052wk High
-0.00Volume Ratio
141.21MNet Profit
107.33MShares
0.4580EPS TTM
0.46Beta
7.17%ROE
28.66052wk Low
3.02%Amplitude
98.25%Gross Margin
9.44BMarket Cap
7.75Reward/Risk
3.42%Risk Rate
TradingKey Stock Score of Corcept Therapeutics Inc
Currency: USD Updated: 2026-06-29Key Insights
Corcept Therapeutics Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 59 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 88.00.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Corcept Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Corcept Therapeutics Inc Highlights
StrengthsRisks
Corcept Therapeutics Incorporated is a commercial-stage company. The Company is engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. The Company operates through the discovery, development and commercialization of the pharmaceutical products segment. The Company has marketed Korlym (mifepristone) in the United States for the treatment of patients suffering from Cushings syndrome. The Company’s portfolio of selective cortisol modulators consists of four series totaling approximately 1,000 compounds. Its portfolio of selective cortisol modulators consists of relacorilant, dazucorilant and miricorilant. Korlyms active ingredient, mifepristone, reduces the binding of excess cortisol to the GR, it can modulate the effects of abnormal levels and release patterns of cortisol without compromising cortisols healthy functions and rhythms.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 57.85% year-on-year.
Overvalued
The company’s latest PE is 191.91, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 76.88M shares, decreasing 9.91% quarter-over-quarter.
Held by John Hussman
Star Investor John Hussman holds 76.22K shares of this stock.
Analyst Rating
Based on
6
analysts
Buy
Current Rating
88.000
Target Price
+0.78%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Corcept Therapeutics Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Corcept Therapeutics Inc Info
Corcept Therapeutics Incorporated is a commercial-stage company. The Company is engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. The Company operates through the discovery, development and commercialization of the pharmaceutical products segment. The Company has marketed Korlym (mifepristone) in the United States for the treatment of patients suffering from Cushings syndrome. The Company’s portfolio of selective cortisol modulators consists of four series totaling approximately 1,000 compounds. Its portfolio of selective cortisol modulators consists of relacorilant, dazucorilant and miricorilant. Korlyms active ingredient, mifepristone, reduces the binding of excess cortisol to the GR, it can modulate the effects of abnormal levels and release patterns of cortisol without compromising cortisols healthy functions and rhythms.
Ticker SymbolCORT
CompanyCorcept Therapeutics Inc
CEOBelanoff (Joseph K)
Websitehttps://www.corcept.com/
Related Instruments
+0.08%
+0.36%
+0.51%
-0.45%
-0.22%
+0.03%
+0.23%
+0.68%
-0.52%
+0.12%
0.00%
0.00%
+0.23%
-0.76%
+0.06%
0.00%
0.00%
0.00%
0.00%
0.00%Popular Instruments
FAQs
What is the current price of Corcept Therapeutics Inc (CORT)?
The current price of Corcept Therapeutics Inc (CORT) is 87.89.
What is the symbol of Corcept Therapeutics Inc?
The ticker symbol of Corcept Therapeutics Inc is CORT.
What is the 52-week high of Corcept Therapeutics Inc?
The 52-week high of Corcept Therapeutics Inc is 91.00.
What is the 52-week low of Corcept Therapeutics Inc?
The 52-week low of Corcept Therapeutics Inc is 28.66.
What is the market capitalization of Corcept Therapeutics Inc?
The market capitalization of Corcept Therapeutics Inc is 9.44B.
Is Corcept Therapeutics Inc (CORT) currently rated as Buy, Hold, or Sell?
According to analysts, Corcept Therapeutics Inc (CORT) has an overall rating of Buy, with a price target of 88.00.
What is the Earnings Per Share (EPS TTM) of Corcept Therapeutics Inc (CORT)?
The Earnings Per Share (EPS TTM) of Corcept Therapeutics Inc (CORT) is 0.96.
